Incara Trading Symbol Changed to ICRA

Incara Trading Symbol Changed to ICRA 


RESEARCH TRIANGLE PARK, N.C., Dec. 17  /PRNewswire-FirstCall/ -- Incara
Pharmaceuticals Corporation ( http://www.incara.com/ ) announced today that as a
result of its recent corporate reorganization, NASDAQ has changed its stock
trading symbol to ICRA.  In November 2003, Incara completed a corporate
reorganization that consisted of the merger of Incara Pharmaceuticals into one
of its wholly owned subsidiaries.  Incara common stock was converted into common
stock of the merged company.  The common stock will continue to trade as Incara
Pharmaceuticals Corporation on the OTC Bulletin Board with the symbol changed to
ICRA, effective today.

Incara Pharmaceuticals Corporation is developing a new class of small molecule
catalytic antioxidants that destroy oxygen-derived free radicals, believed to be
an important contributor to the pathogenesis of many diseases. Incara's
catalytic antioxidants have been shown to reduce damage to tissue in animal
studies of neurological disorders such as amyotrophic lateral sclerosis (Lou
Gehrig's disease, also known as ALS) and stroke, and in other non-neurological
indications such as cancer radiation therapy, chronic bronchitis and asthma.

The statements in this press release that are not purely statements of
historical fact are forward-looking statements, and actual results might differ
materially from those anticipated.  These statements and other statements made
elsewhere by Incara or its representatives, which are identified or qualified by
words such as "intends," "likely," "will," "suggests," "expects," "might,"
"may," "believe," "could," "should," "would," "anticipates," "plans," or the
negative of those terms or similar expressions, are based on a number of
assumptions that are subject to risks and uncertainties.  Important factors that
could cause results to differ include risks associated with the immediate need
to obtain funds for operations, uncertainties of scientific research, clinical
trials and product development activities.  These and other important risks are
described in Incara's reports on Form 10-K, Form 10-Q and Form 8-K and its
registration statements filed with the Securities and Exchange Commission. 
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof.  Incara assumes no
obligation to update the information in this release. 

DATASOURCE: Incara Pharmaceuticals Corporation



CONTACT:  W. Bennett Love of Incara Pharmaceuticals Corporation,

[phone]



Web site:  http://www.incara.com/ 

Copyright